China Biopharmaceuticals (01177.HK): The first subject has been dosed with Category 1 innovative drug TQB6411 (EGFR/c-MET bispecific ADC) via injection.

Guotong Financial APP news, China Biopharmaceuticals (01177.HK) announced that the group's independently developed first-in-class innovative drug injection TQB6411 (EGFR/c-Met bispecific ADC) recently completed the entry of the first subject in Phase I clinical study in China and successfully administered the drug. TQB6411 was approved by the National Medical Products Administration (NMPA) on June 13 to conduct clinical trials for the treatment of advanced malignant tumors. Currently, the R&D progress is at the forefront globally, with all similar drugs worldwide still in the Phase I stage.